{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:10:34Z","timestamp":1781241034463,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease Markers"],"published-print":{"date-parts":[[2022,9,5]]},"abstract":"<jats:p>Objective. To explore the effect of dapagliflozin on the myocardial fibrosis and the levels of inflammatory factors in heart failure patients. Methods. 60 patients with T2DM who were diagnosed as acute left heart failure or acute exacerbation of chronic left heart failure in the Department of Cardiology of our hospital from November 1, 2020, to December 31, 2021, during hospitalization were the study subjects. According to the treatment regimen, they were divided into the experimental group (EG) which received dapagliflozin and conventional drugs and the control group (CG) which received conventional drugs, with 30 cases in each group to compare and analyze the clinical indicators such as myocardial fibrosis and inflammatory factors. Results. The levels of TNF-\u03b1, IL-1\u03b2, IL-6, and hs-CRP in the two groups were decreased gradually after treatment, and the levels of TNF-\u03b1, IL-1\u03b2, IL-6, and hs-CRP in the EG were visibly lower compared with those in the CG at week 4 of treatment (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>&lt;<\/a:mo>\n                        <a:mn>0.05<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>). The cardiac function evaluation of patients showed that the levels of LVEF and LVEDD in both groups were gradually improved after treatment, with a significant difference from the fourth week. In other words, compared with the CG, the LVEF level in the EG was obviously higher (<jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                        <c:mo>&lt;<\/c:mo>\n                        <c:mn>0.05<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>), the LVEDD level was distinctly lower (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                        <e:mo>&lt;<\/e:mo>\n                        <e:mn>0.05<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>), and the levels of ST2, BNP, and MCP-1 in the EG were clearly lower at week 4 of treatment (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>&lt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>) with a statistical significance in difference. Conclusion. Dapagliflozin has a definite curative effect in heart failure patients with type 2 diabetes mellitus, which can effectively reduce the inflammatory response of patients and inhibit the myocardial fibrosis, and has a potential value in improving cardiac function and promoting prognosis.<\/jats:p>","DOI":"10.1155\/2022\/5834218","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T18:05:08Z","timestamp":1662401108000},"page":"1-7","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients"],"prefix":"10.1155","volume":"2022","author":[{"given":"Chuanqiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Third Hospital of Hebei Medical University, 050051 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiteng","family":"Qin","sequence":"additional","affiliation":[{"name":"Basic Medicine College, Hebei Medical University, 050017 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Hospital of Hebei Medical University, 050051 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Hospital of Hebei Medical University, 050051 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Hospital of Hebei Medical University, 050051 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Hospital of Hebei Medical University, 050051 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Qin","sequence":"additional","affiliation":[{"name":"Hebei Orthopedic Research Institution, 050051 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-6646","authenticated-orcid":true,"given":"Ke","family":"Chen","sequence":"additional","affiliation":[{"name":"Catheter Room, Third Hospital of Hebei Medical University, 050051 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7931-0535","authenticated-orcid":true,"given":"Wenliang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Third Hospital of Hebei Medical University, 050051 Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"issue":"15","key":"1","first-page":"936","article-title":"Efficacy and safety evaluation of dagglitazone in the treatment of type 2 diabetes with chronic heart failure","volume":"18","author":"F. Xianu","year":"2021","journal-title":"Drug evaluation"},{"issue":"17","key":"2","first-page":"47","article-title":"Effects of dagglitazone on insulin resistance, blood lipid, and Hcy in patients with type 2 diabetes mellitus","volume":"31","author":"H. Liangweihua","year":"2021","journal-title":"Shenzhen Journal of integrated traditional Chinese and Western medicine"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2017.08.456"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318159"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.118.007722"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.021"},{"issue":"3","key":"7","first-page":"1639","article-title":"Effects of ivabradine hydrochloride combined with trimetazidine on myocardial fibrosis in rats with chronic heart failure","volume":"18","author":"D. W. Ma","year":"2019","journal-title":"Experimental and Therapeutic Medicine"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2019.06.001"},{"key":"9","first-page":"165","article-title":"Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with nonischemic systolic heart failure-DANISH-MRI","volume":"221","author":"M. B. Elming","year":"2019","journal-title":"Autonomic Neuroscience: Basic & Clinical"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.10.018"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.01.003"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.05.009"},{"key":"13","article-title":"Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice","volume":"133, article 110824","author":"Y. Liu","year":"2021","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01536-x"},{"issue":"1","key":"15","first-page":"S101","article-title":"A SGLT2 inhibitor dapagliflozin prevents heart failure with preserved ejection fraction through activating mitophagy in ZDF diabetic rats","volume":"62","author":"B. Feng","year":"2019","journal-title":"Diabetologia: Clinical and Experimental Diabetes and Metabolism Organ of the European Association for the Study of Diabetes (EASD)"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01406-3"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-020-00825-x"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1576479"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13126"},{"issue":"3","key":"20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 inhibitors in heart failure: diabetes and beyond","volume":"19","author":"P. Martens","year":"2017","journal-title":"Current Treatment Options In Cardiovascular Medicine."},{"issue":"2","key":"21","first-page":"18","article-title":"SGLT2 inhibitors and heart failure outcomes","volume":"45","author":"C. Chim","year":"2020","journal-title":"U. S. pharmacist"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318060"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008365"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1432"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112169"}],"container-title":["Disease Markers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/5834218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/5834218.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/5834218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T18:05:21Z","timestamp":1662401121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/dm\/2022\/5834218\/"}},"subtitle":[],"editor":[{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":25,"alternative-id":["5834218","5834218"],"URL":"https:\/\/doi.org\/10.1155\/2022\/5834218","relation":{},"ISSN":["1875-8630","0278-0240"],"issn-type":[{"value":"1875-8630","type":"electronic"},{"value":"0278-0240","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,5]]}}}